Microbot Medical financials
$1.25−0.40%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $241.0K | $105.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$643.0K | $2.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | −266.8% | 1.9% | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$6.2M | -$4.3M | -$4.1M | -$3.9M | -$3.7M | -$3.0M | -$3.4M | -$3.3M | -$2.5M | -$2.4M | -$2.1M | -$2.5M |
| Net income | -$5.6M | -$3.7M | -$3.5M | -$3.6M | -$3.5M | -$2.6M | -$3.4M | -$3.2M | -$2.5M | -$2.4M | -$3.2M | -$2.4M |
| Net margin | −2334.9% | −3496.2% | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.08 | $-0.05 | $-0.05 | $-0.07 | $-0.10 | $-0.08 | $-0.20 | $-0.20 | $-0.17 | $-0.17 | $-0.27 | $-0.21 |
| EBITDA | -$6.2M | -$4.3M | -$4.1M | -$3.9M | -$3.7M | -$3.0M | -$3.4M | -$3.3M | -$2.5M | -$2.4M | -$2.0M | -$2.5M |
| Operating cash flow | -$5.0M | -$5.1M | -$3.8M | -$3.8M | -$2.6M | -$2.9M | -$1.7M | -$2.8M | -$2.0M | -$2.4M | -$1.8M | -$1.7M |
| Free cash flow | -$5.1M | -$5.2M | -$3.8M | -$3.9M | -$2.6M | -$2.9M | -$1.7M | -$2.8M | -$2.0M | -$2.4M | -$1.8M | -$1.7M |
| Diluted shares | 67.2M | 67.2M | 67.5M | 48.1M | 36.5M | 31.1M | 17.2M | 16.5M | 14.8M | 14.1M | 11.9M | 11.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.2M | $3.7M | $3.9M | $6.7M | $4.1M | $3.2M |
| Short-term investments | $64.2M | $68.8M | $74.7M | $73.5M | $28.6M | $27.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $73.4M | $78.1M | $81.5M | $81.8M | $33.1M | $30.9M |
| Total liabilities | $4.4M | $4.0M | $4.0M | $3.5M | $2.8M | $1.9M |
| Shareholders' equity | $68.9M | $74.1M | $77.6M | $78.2M | $30.4M | $29.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology